CLINUVEL's afamelanotide implant, the world's first systemic photoprotective drug, has won approval in Canada for preventing phototoxic reactions in adults with erythropoietic protoporphyria (EPP) — a rare disorder where daylight causes severe pain and burns. Canada becomes the fourth major market for the 16 mg implant after Europe, the USA and Australia, where it has now been given more than 21,000 times.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.